Drug Trial Radar · NCT06333249
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Actual
Start
Apr 13, 2021
Primary completion
Apr 11, 2023
Study completion Feb 2027
Sponsor
- Lead sponsor
- Beacon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 8 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGRBiological
Adeno-associated virus vector expressing a human RPGR gene
Primary outcomes
What the sponsor says the trial is designed to measure.
- The difference in the proportion of responding eyes between treated and control eyes in the low dose group and high dose group at 12 months, as measured by MAIA microperimetry, where response is defined as a 7dB or more improvement in at least 5 loci.Time frame: Day 0 - Month 12
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Florida
Jacksonville, Florida
Boston Children's Hosptial
Boston, Massachusetts
Cincinnati Eye Institute
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Casey Eye Institute
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.